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Abstract

Alzheimer’s disease is a neurodegenerative disease with no early diagnosis.
Neuronal dysfunction is an early indication of Alzheimer’s disease which we can measure
by examining the lysosomal protein Cathepsin-D. Molecular imaging of Cathepsin-D
using Magnetic Resonance Imaging (MRI) contrast agents could enhance visualization of
disease and provide contrast within tissues and cells that are morphologically similar but
physiologically distinct.

The purpose of our work was to evaluate a novel

MRI/fluorescent contrast agent designed to detect Cathepsin-D in early Alzheimer’s
disease.
In-vitro MRI and fluorescent sensitivity were characterized in addition to cellular
uptake in cells over-expressing Cathepsin-D.

Cortical and hippocampal uptake was

evaluated following in-vivo injection of contrast agent in mice.

The contrast agent

exhibited differences in retention and uptake between control and transgenic Alzheimer’s
mice.

The results demonstrate the potential utility of the contrast agent for in-vivo

identification of cathepsin-D upregulation and will continue to be further evaluated and
refined in future studies.

Key Words: Alzheimer’s Disease, contrast agent, cathepsin-D, magnetic resonance
imaging, cell-penetrating peptide, live cell imaging
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Chapter 1: Introduction
1.1

Introduction
The work in this thesis is focused on Magnetic Resonance Imaging (MRI) and

fluorescence imaging to study contrast agents designed to detect enzyme activity with an
application to the diagnosis of early Alzheimer’s disease (AD). These imaging modalities
were used to test and characterize the sensitivity and molecular behavior of newly
developed contrast agents.
The following chapter provides an introduction to the physiological and cellular
changes that occur in Alzheimer’s disease, a background on magnetic resonance and
fluorescence imaging, and their application of these methods to brain imaging.
Preliminary work performed on the synthesis, design, and testing of a dual
MRI/fluorescent contrast agent is also presented from a manuscript published in Organic
and Biomolecular Chemistry, entitled A Paramagnetic Chemical Exchange-Based MRI
Probe Metabolized by Cathepsin-D: Design, Synthesis, and Cellular Uptake Studies.

1.2

Alzheimer’s Disease
Alzheimer’s disease is a neurodegenerative process that destroys neurons in the

brain and ultimately leads to impaired cognitive function and death [1,2]. It was first
described by Alois Alzheimer in 1906 when he observed deposits of plaques in the post
mortem examination of a patient [3]. Alzheimer’s disease is the most common form of
dementia, which is a group of symptoms found in other diseases such as vascular
dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, and Lewy-body dementia
[4].
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1.2.1

Alzheimer’s Disease Pathology
Since Alois Alzheimer originally observed extracellular plaques and intracellular

neurofibrillary tangles (NFTs), these have remained the gold-standard in diagnosing AD
neuropathology [2],

However, the exact biological mechanism of AD continues to

remain a mystery. Over time, research has identified several key mechanistic theories to
explain its initiation and progression, which are now dominated by the amyloid cascade
hypothesis.

Although plaques and NFTs are used as diagnostic criteria, it would be

misleading to state that these are the only significant pathological changes occurring in
the AD brain.

In fact, numerous other structural and functional alterations ensue,

including inflammatory responses and oxidative stress [5-8], The combined consequence
of all these pathological changes, including the effects of the Ap and tau pathologies, is
severe neuronal and synaptic dysfunction and loss. The National Institute of AgingAlzheimer’s Association had recently refined the diagnosis of AD [9]. However, it still
contains the original framework of diagnostic criteria outlined in 1984 with the addition
of research knowledge including new biomarkers and imaging to increase the sensitivity
of diagnosis.
The amyloid cascade hypothesis has been challenged as an accurate model of AD
initiation and pathogenesis, particularly due to the discovery of significant Ap loads in
non-demented individuals, the absence of such loads in demented individuals, and poor
correlation between plaque clearance and that of rescued cognitive function [10]. Models
placing inflammation and neurofibrillary tau tangles at the forefront of AD pathology
have been offered as alternatives [10-12], The discrepancies outlined with the amyloid
cascade hypothesis may be explained with a new theory that states pre-fibrillar, nonassembled P-amyloid is just as toxic as its assembled counterpart [13]. There have been

3

an increasing number of these studies in the literature that support this theory through
synthetic A(] peptides, cell culture models, P-amyloid precursor protein transgenic mice
and human brain [14-16].

1.2.1.1 Lysosomal System
The remarkable abundance of undigested protein within accumulated autosomal
vacuoles (AV), many of which contain lysosomal proteases, strongly implies a defect in
the proteolytic clearance of autophagy substrates by lysosomes.

In this regard,

comparable levels of protein “storage” in the brain are most often observed in certain
primary lysosomal storage diseases associated with severe cognitive disabilities and
neurodegenerative phenotypes that share key neuropathological features of AD [17, 18].
Further implicating primary dysfunction of the lysosomal system in AD is evidence for a
continuum of abnormalities within endocytic and autophagic pathways connected to
lysosomes, some linked directly to genes causing early-onset AD [19-21], As a result,
our work has been designed to seek out this lysosomal dysfunction in AD.

1.2.1.2 Cathepsin-D
Cathepsin-D (Cat-D) is a member of the aspartyl protease family found in all
mammalian cells and normally localized to the lysosome [22, 23], Studies involving CatD have shown that it plays a role in several physiological functions including protein
degradation, apoptosis, and autophagy [24],

Cat-D is synthesized on the rough

endoplasmic reticulum as a pre-pro-enzyme. This pre-pro-cathepsin-D contains an Nterminal secretion signal peptide that is removed during transport of the enzyme across
the endoplasmic reticulum membrane. The result is an inactive pro-Cat-D enzyme with a
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size of 52 kDa. The pro-Cat-D enzyme is transported to the Golgi for further processing.
The mannose-6-phosphate (M6P) pathway mediates the transport of pro-Cat-D to the
lysosome from the golgi [25]. The M6P pathway helps to package the pro-Cat-D into
vesicles to eventually deliver it to lysosomes.

Once pro-Cat-D reaches lysosomal

compartments, the low pH causes pro-Cat-D to be released from the M6P receptors and
also the phosphate group is removed. The pro-peptide is then removed leaving Cat-D in
an active intermediate form (48 kDa).

The intermediate form is further cleaved by

cathepsin B or L to form mature Cat-D consisting of a closely associated light chain (14
kDa) and a carboxyl-terminal heavy chain (34 kDa) [26].
Cathepsin D (Cat-D) is over-expressed in several types of cancers and in
Alzheimer’s disease, which makes it a potentially useful biomarker for these diseases.
Specifically, Cat-D is upregulated in breast cancer [27], ovarian cancer [28], endometrial
cancer [29], and prostate cancer [30], and has been associated with increased risk of
metastasis [31].

Cat-D may be involved in processes of early tumour progression

including the stimulation of cell proliferation, fibroblast outgrowth and angiogenesis [32],
Therefore, the detection of over-expression of this protease may have prognostic value
and help to identify subjects that require treatment, making it an excellent target as an
imaging biomarker.

With respect to Alzheimer’s disease (AD), a prevalent

neurodegenerative brain disorder, it has been well documented that increased levels of
lysosomal hydrolases in normal appearing neurons precede the earliest known
histopathological features of AD [33], Over-expression, up to four times the normal
expression of Cat-D [34-37], in Alzheimer’s disease patients also makes this protease a
viable imaging biomarker for in-vivo AD detection since very early clinical diagnosis
remains difficult [38],

5

Polymorphisms in the Cat-D gene have also been loosely correlated with an
increased risk for sporadic AD [39, 40] and Cat-D activity has been shown to increase
early in AD [33]. Yet other studies alternately indicate a positive role for Cat-D in the
degradation of toxic protein accumulations in-vivo, such as the alpha-synuclein, A[142,
and tau aggregations which encompass the hallmark pathologies of Lewy Body and AD
dementia [41]. Thus, while research has established Cat-D within a selection of ADassociated pathways, it remains unclear whether Cat-D plays an aggravating or restorative
role in AD neuronal apoptosis.

1.2.2

Clinical Evaluation and Diagnosis of Alzheimer’s Disease
The early onset of Alzheimer’s disease typically occurs from before 60 years of

age with chronic neurodegeneration until death at about six years following onset [42-44],
The brain eventually displays significant atrophy; however, age-associated atrophy and
the normal variability in brain size preclude a diagnosis based solely on gross
examination of the brain [45],

Large scale atrophy of the temporal lobe is often

pronounced in comparison to other areas of the cortex.

In most cases, the primary

sensory and motor cortices are relatively spared and on sectioning the brain, the lateral
ventricles are usually dilated and the hippocampus and amygdala are atrophic [45],
There are standardized cognitive and memory tests that neurologists include as
tools to help aid in their diagnosis of Alzheimer’s disease. For example, the Mini-Mental
State Exam (MMSE) is utilized by physicians to assess a patient’s memory, attention
span, and problem solving skills [46]. The results provide insight into what areas of the
brain may have been affected by the disease. These tests along with a clinical assessment
and the process of elimination of other diseases provide physicians with up to 90% rate of
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success in diagnosing individuals with Alzheimer’s disease [47-49],

Neurologists

specializing in the dementias have the greatest accuracy while general practitioners have
the lowest [45], This accuracy drops even further when these patients exhibit other kinds
of related dementias [50], However, studies have also shown that the MMSE’s ability to
predict or detect Alzheimer’s disease at an earlier stage declines in accuracy [51], Early
detection and diagnosis is important so patients and their families understand what to
expect and how to care for their family member. In addition, earlier diagnosis gives
patients and their families time to discuss preventative measures such as lifestyle changes
and to look after any future needs of the patient. Lastly, certain types of Alzheimer’s
disease drugs may be most effective during the early onset of the disease before major
cognitive deficits occur [52],
At the current time, the only definitive way to diagnose Alzheimer’s disease is
with a post-mortem histological examination of the brain [2],

Individuals with

Alzheimer’s disease have an increased deposition of |3-amyloid plaques within the brain.
Neurofibrillary tangles (tau protein) are also present at higher than normal quantities
within the brain.

1.2.3

Clinical Treatment of Alzheimer’s Disease
Most drugs on the market today provide symptomatic relief but do not affect

Alzheimer’s disease progression. For example, acetylcholinesterases such as Donepezil
act on the central nervous system by inhibiting acetylcholinesterase, an enzyme that
breaks down the neurotransmitter acetylcholine [53].

By inhibiting the enzyme that

breaks down the neurotransmitter acetylcholine, acetylcholine remains free to interact
with postsynaptic neuron(s) allowing the nervous signal to propagate further. Such drugs
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have been proven to temporarily provide cognitive benefit, slow functional decline, and
help behavioural symptoms [54-57], Other acetylcholinesterase drugs approved by the
FDA are Galantamine, Rivastagmine, and Tacrine that provide a similar mechanism of
action as Donepezil. However, affected individuals eventually begin to demonstrate the
same cognitive decline as other individuals not on a clinical drug treatment.
Another class of AD drug is a blocker of /V-methyl-D-aspartic acid glutamate
receptors (NMDARs).

Memantine is a drug that partially blocks the NMDAR and

prevents excess stimulation of the glutamate system, which influences memory and
learning [58], To date, no drug has been discovered at this time to stop or reverse the
progression of Alzheimer’s disease.

1.2.4 Alzheimer’s Disease in Canada
Alzheimer’s disease is a debilitating disease and its greatest risk factor is
increasing age [59, 60], In Canada, as the average age of the population extends well into
the ninth decade, there will be an increasing number of individuals afflicted with
Alzheimer’s disease. Currently, this number stands at half a million people, and within a
generation this number is expected to at least double to over one million [61]. The direct
and indirect costs for treating individuals with Alzheimer’s disease and the monetary
wage losses for their family members is expected to surpass the $150 billion dollar mark
within one generation [61]. Studies around the world have also indicated that as the
severity of the disease increases, so do the associated costs with taking care of these
individuals [62-64], Alzheimer’s is more than just an important health concern, it has the
potential to overwhelm the Canadian health care system and may become the highest
economic, social and health cost burden of all diseases. As a result, prevention, early
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detection, and treatment have become a top healthcare priority of many nations around
the world, including Canada.

1.2.5

Challenges to Early Detection of Alzheimer’s disease
The fundamental challenge to early diagnosis of Alzheimer’s disease is that the

disease is currently defined histopathologically by confirmation of neuritic plaques and
tangles in the post-mortem brain, but the diagnosis is made based upon clinical
symptoms.

There is an assumption made about the causal linkage between the

histopathology and the cognitive symptoms. Another assumption is that the correlation
between pathology and symptoms can be measured accurately and reliably with currents
cognitive tests. However, many studies have questioned these assumptions and have lead
researchers to conclude that the current diagnostic criteria based on the National Institute
of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and
Related Dementia Association (NINCDS-ADRDA) criteria and the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria are inadequate for
guiding clinical care and evaluation of therapeutic drugs. In addition, there is evidence
that irreversible damage has already occurred by the time symptoms appear [65]. Thus,
new biomarkers must be developed and validated to measure effects directly related to the
disease process.

Yet, there are several difficulties to the rapid development of

biomarkers: 1) an incomplete understanding of the Alzheimer’s disease process, 2) the
complexities related to the comorbidities of other types of dementia (i.e. vascular
dementia) that have similar symptoms to Alzheimer’s disease, and 3) the cost associated
with biomarker development and validation.
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Currently, several types of potential imaging biomarkers have been developed for
the early detection of Alzheimer’s disease. Molecular probes differ in sensitivity and the
imaging technique(s) used to detect a biological change within the Alzheimer’s brain.
For instance, the Pittsburgh B compound (PIB) preferentially binds to |3-amyloid plaques
in the brain and was designed with both a fluorescence tag and radionuclide for positron
emission tomography (PET) scanning [66], In the pre-clinical stage of development,
researchers utilized multi-photon confocal imaging to visualize the distribution of the
compound within the transgenic Alzheimer’s disease mouse. In the clinical phase, they
were able to inject normal elderly controls and Alzheimer’s disease patients with the
compound and visualize uptake of compound in the brain using PET imaging [67],
Subjects with Alzheimer’s disease demonstrated a significant uptake in the brain
compared to normal elderly controls.

Consequently, this compound can provide

additional information to physicians to help increase diagnostic accuracy in an individual
with Alzheimer’s disease.

The development of this compound provides an example

where both fluorescence and PET imaging were used to objectively evaluate the
biomarker’s capabilities in detecting (3-amyloid plaques. Although proven successful at
detecting (3-amyloid plaques, the PIB compound ability to accurately predict pre-clinical
AD in human patients is still under investigation.

1.2.6

Pre-Clinical Models of Alzheimer’s Disease

1.2.6.1 Cellular Models of AD
Pre-clinical cellular experiments provide the stepping-stone to in-vivo animalbased experiments. Cellular models of diseases allow for the examination of biological
events at the molecular level. Our laboratory choose to work with the SN56 neuronal cell
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line, a fusion between septal neurons and neuroblastoma cells [68]. Once these cells have
been differentiated, they highly resemble neurons as they exhibit many cholinergic
properties (Figure 1.1) [69, 70]. The goal of creating medial septal neurons was to
immortalize cholinergic neurons from the nucleus basalis of Meynert. This is a group of
neurons that are affected in AD [71, 72].

Figure 1.1: SN56 neuronal cell culture as seen from a brightfield light image (63x lens).
Neuronal morphology and neurite extensions are well developed in cell culture.

1.2.6.2 Mouse Models of AD
Mouse models of disease provide us with an important understanding of not only
the mechanisms of disease but also provide an opportunity to test disease modification
through treatment. Differences between mice and humans are just as important as the
similarities. Mice are small, prolific, and scientists are able to manipulate their genes to
mimic a disease which is not possible with humans. Transgenic mice are genetically
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modified model such that the condition or disease has been induced via the manipulation
of the genetic code.

These mice provide a platform to test new treatments and the

monitoring of those treatments.

Some drugs need to be rigorously tested in animal

models in order to move to human clinical trials. For example, immunization against
amyloid plaques in mice showed that plaques could be cleared from the brain [73], As a
result, mouse models of Alzheimer’s disease may offer insight into the pathological
mechanisms as well as new drug discoveries.
Many mouse models of Alzheimer’s disease contain one or more genetic
mutations that lead to excessive plaque formation. Amyloid Precursor Protein (APP) and
Presenilin-1 and -2 (PS1, PS2) are genes discovered to cause early onset Alzheimer’s
disease in humans [74], Although early onset is a small minority of all Alzheimer’s
disease cases, it provided researchers the opportunity to further study the biological
mechanisms behind Alzheimer’s disease pathology. For instance, at 12 months of age,
transgenic APP/PS1 mice exhibited extensive plaque deposition within the hippocami as
seen on Figure 1.2. Another variant of the presenilin-1 mutation is the deletion of the
exon 9 (dE9) within the presenilin-1 gene. This caused early neurofibrillary tangles and
plaques to form within the brains of humans [75]. Many mouse models of AD continue
to be created and although the complete mechanism has yet to be discovered, important
insights have been provided into the pathobiology of AD. Therefore, utilizing transgenic
mouse models will continue to be important to understanding disease progression and
advanced drug development to effectively treat AD.
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Figure 1.2: Amyloid plaque (black) staining in the hippocampus of a 12 month-old
transgenic mouse stained using an antibody to P-amyloid protein.

1.2.7

Biomarkers of Disease
Biological markers may indicate a variety of disease characteristics, from the level

of exposure to an environmental or genetic trigger, a process of the disease itself, an
intermediate stage between exposure and disease onset or an independent factor
associated with the disease but not directly contributing to the pathology.

Specific

biomarkers may be designed to identify the risk of developing a disease, aid in identifying
disease, or predict future disease progression such as response to therapy.
According to the National Institutes of Health (NIH), a biomarker is “a
characteristic that is objectively measured and evaluated as an indicator of normal
biologic processes, pathogenic processes, or pharmacological responses to a therapeutic
intervention.” The ideal biomarker would meet this criterion and in addition be noninvasive and cost-effective. In order for these biomarkers to be designed, tested, and
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developed, pre-clinical models of diseases should be utilized prior to human clinical
trials.

1.3

Molecular Imaging of Contrast Agents

1.3.1

Contrast Agents in Imaging
The purpose of utilizing contrast agents is to enhance or highlight specific areas

on an image. More specifically, contrast agents change the properties of the tissues or the
surrounding areas to increase the contrast on medical images. For example, gadolinium
changes the properties of water by causing it to relax faster than the surrounding tissue,
thus leading to a brighter signal on a Ti-weighted image [76]. Similarly, fluorescence
based contrast agents allow tracking of agents at the cellular level and the ability to
observe many molecular interactions [77, 78],

1.3.2

Non-Specific and Targeted Contrast Agents
Contrast agents may accumulate in tissue due to leakage of the vasculature, or

they may be targeted to specific cellular constituents and therefore accumulate where
over-expression occurs.

Gadolinium-based contrast agents are an example of a non

specific contrast agent that after injection into the bloodstream, it will diffuse into a
particular tissue or organ only when there is a perforation or increased permeability
within the blood vessels walls [79], It normally continues to circulate throughout the
body and will be eventually filtered and excreted by the kidneys.
Specific contrast agents have a molecular component that enables them to
recognize enzymatic, receptor, cellular, tissue or organ targets. The addition of a specific
ligand allows the contrast agent to be recognized by a particular biological object.
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Identification of viable targets is often a significant challenge, and determination of
optimal amino acid ligands with the highest affinity for the biological target often takes
considerable effort. To further our understanding of molecular and pathological events,
specific contrast agents may be imaged to improve our understanding of these processes.

1.3.3

Multi-Modality Contrast Agents for Disease Detection
Imaging modalities can be broadly divided into primarily anatomical and

primarily molecular imaging techniques.

Anatomical imaging technologies such as

computed tomography (CT), MRI (with contrast agents injected at millimolar blood
concentrations) and ultrasound, are characterized by high spatial resolution. However,
they also share the limitation that these technologies are often unable to detect disease
until gross tissue structural changes, for example, cerebral atrophy in AD patients, are
present. Molecular imaging modalities such as optical imaging, PET and SPECT (with
radiotracers injected at nanomolar blood concentrations) offer the potential to detect
minute molecular and cellular changes associated with disease. In this case, often before
the atrophy causes visible structural changes. However, these modalities suffer from a
poor spatial resolution with currently available technology.
Combining the strengths of anatomical and molecular imaging modalities (using
multimodality hardware and/or co-registration post-acquisition processing) allows the
detection of pathophysiological changes in early disease phases with high structural
resolution. Other technologies such as high-resolution multidetector and dual-source CT
technology with high temporal resolution and volumetric reconstruction capabilities,
dynamic contrast enhanced MRI and CT, as well as magnetic resonance spectroscopy
(MRS) are blurring the distinction between morphological and molecular imaging by also
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providing functional information. These technologies may change the current primarily
technology-driven approach of diagnostic imaging into a more disease-oriented approach
for both basic research and clinical application. Some novel contrast agents have also
been designed for use with two or more imaging modalities. A few examples includes the
PET/CT/MRJ contrast agent for atherosclerotic lesions [80] and similar high-density
lipoprotein nanoparticles [81].

1.3.4

Contrast Agents for Enzymatic Activity
Many novel contrast agents have been designed to detect a biological target to aid

in disease detection or observation.

Specifically, imaging probes with enzymatic

recognition incorporated into their molecular design are gaining popularity. Enzymes are
proteins that help facilitate biochemical reactions.

Proteases are specific kinds of

enzymes that recognize and cleave specific substrates [82]. Substrates are the compounds
that undergo a change after being worked on by the enzyme to yield products. The
induced-fit theory of enzyme-substrate interaction describes how enzymes are able to
accommodate several types of substrates within their active sites. The active site is where
the enzymatic cleavage of a substrate occurs [83], More importantly, an enzyme will
usually only recognize amino acids with a particular sequence and therefore can be
targeted by a contrast agent that incorporates this sequence into the design of the agent.
Typically an enzyme-substrate interaction lasts for microseconds after which the enzyme
is ready to cleave the next substrate. As a result, substrates designed to detect enzymatic
activity have the ability to be specifically and highly targeted.
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1.4

Fluorescence Imaging

1.4.1

Fluorescence/Optical imaging
Fluorescence imaging has become a powerful and common technique throughout

the life sciences [84, 85], This imaging modality has the capability of imaging molecular
events due to the extremely high detection sensitivity [86], Fluorescence occurs when a
fluorochrome or a fluorophore absorbs energy from an external source, for example from
a laser, then emits parts of this absorbed energy as light of another colour [87]. There are
three main steps in the fluorescence process.

First, excitation of electrons occurs.

Electrons are raised to a higher energy level and vibrational excited state due to the
absorption of energy from a photon of light. Next, in the transitional state, the excited
electrons may lose some vibrational energy to the surrounding environment and decrease
to a lower excited state.

Lastly, the emission phase occurs where we observe

fluorescence. At the lowest excited state, electrons are able to give off the rest of their
energy to return to the ground state emitting the absorbed energy as fluorescent light.
Since less energy is emitted than absorbed due to the transition step, the emitted light is
always of longer wavelength than the excitation light. This is known as Stokes Law [87],
A fluorochrome can be excited with different wavelengths within its excitation spectrum
and subsequently emits light within a characteristic range of wavelengths referred to as
the emission spectrum. The amplitude of the emission spectrum is determined by the
efficiency of excitation.
Fluorescent imaging continues to dominate cellular and tissue imaging because of
its high spatial resolution, its compatibility with standard microscopy techniques and
hardware, and its ability to detect small concentrations of fluorescent compounds or
fluorescently tagged proteins. As a result, many multi-modality probes or contrast agents
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are still being synthesized with fluorescent imaging in mind to capitalize on the high
sensitivity of fluorescent imaging [88-93],

1.4.2

Laser Scanning Confocal Microscopy
Laser scanning confocal microscopy has an advantage over normal widefield

microscopy because the light can be collected from a single plane, which could be several
microns thick [94], The optical sectioning is accomplished by a pinhole placed in the
emission pathway at a position where only emission originating from the focal plane is
able to pass through the detector and out-of-focus emission is blocked. This technique
allows for the precise capture of information at the molecular level.

1.5

Magnetic Resonance Imaging
Magnetic resonance imaging provides a non-invasive method of looking into the

structures of the brain. Unlike fluorescence imaging, it is easily possible to acquire stacks
of images with a specified slice thickness. It is possible to acquire images of any region
of the body as long as the region of interest fits inside the magnet, gradient coil, and radio
frequency coil, and a homogeneous magnetic field can be achieved throughout the tissue.
MR imaging can report both spatial and temporal information related to contrast agent
uptake. MR imaging also provides excellent tissue contrast in the brain and other soft
tissues, which makes MRI an ideal imaging modality of complex structures. However, to
contrast with fluorescent imaging, the spatial and temporal resolution is decreased.
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1.5.1

MRI Contrast Agents in Molecular Imaging
Molecular imaging is a rapidly emerging field of diagnostic medicine that

combines the disciplines of biology, chemistry, medicine, and radiology.

It enables

physicians and researchers to visualize biological processes in a non-invasive way,
observing the biology in action. The potential to use molecular imaging to diagnose
diseases is limitless, however the current primary uses are for the diagnosis for cancer,
cardiovascular, and neurological diseases.
There are many types of contrast agents available for use in magnetic resonance
imaging. The contrast agent chosen depends upon the desired contrast within the image.
For example, iron-labeled particles appear as dark voids on T2-weighted magnetic
resonance images and may be observed by histology to enter tissues or cells [95].
Paramagnetic metals such as gadolinium are substances that contain one or more unpaired
electrons and have a positive magnetic susceptibility. The unpaired electrons interact
with nuclear spins and cause increased rates of relaxation (1/Ti or I/T 2). Gadolinium is
also a lanthanide or “rare earth” metal that has 7 unpaired electrons giving it a relatively
large magnetic moment. The most common clinically used contrast agent are those that
shorten the Ti relaxation time constant of water, increasing signal intensity in T|weighted images in tissue regions where the agent accumulates.

A more recently

developed mechanism of generating contrast in MRI is utilizing Chemical Exchange
Saturation Transfer (CEST) [96-99].

The advantage of utilizing these CEST based

contrast agents is the ability to turn them on and off at will. Therefore, multiple contrast
agents may be used at the same time but their modulation of image signal intensity could
be turned on when required. This method of imaging would unlock many opportunities
to explore the way the human body works using contrast agents.
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1.5.2

MR Physics and Spin
Conventional magnetic resonance imaging utilizes the magnetic properties of the

proton ('H), which is the most abundant nucleus in the human body [100]. A simplified
conceptualization of the way that the MR signal is produced is described below. Each
hydrogen nucleus is can be thought of as spinning on its axis and therefore producing a
rotating positive charge.

The laws of electromagnetism state that a moving charge

induces a magnetic field. Thus, the hydrogen nucleus creates its own tiny magnetic field
called a magnetic moment. In the absence of an external magnetic field, each proton
spins about an axis oriented in random directions. However, when an external magnetic
field is applied to these protons, individual nuclei will experience a force that causes the
spin to align either parallel or anti-parallel with this magnetic field. There is a slight
excess of spins that align parallel to the magnetic field [100].
Although each nucleus experiences a force from the external magnetic field, they
do not fully align with this magnetic field. As a result, they precess, or spin around the
axis of the external magnetic field. This precession may be visualized as a spinning top
that wobbles about its centre of gravity. The frequency of precession about the external
magnetic field is proportional to the magnetic field strength as given by the Larmor
equation:

ooo = y Bo , Y= gyromagnetic ratio, B0 = magnetic field strength

Therefore, all protons precess at a specific frequency called the Larmor frequency when
placed in an external magnetic field.

Summing up all the magnetic moments in the

sample produces a net magnetization in the direction of the applied magnetic field [101].
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1.5.3

Ti, T2, Proton Density Weighting and Relaxation
By exciting the magnetic moments to a higher energy level and bringing them into

phase coherence using radio frequency pulses, and then manipulating the net
magnetization using magnetic field gradients, maps of the spatial distribution of 'H atoms
within the sample can be created called images. The signal intensity at each position in
the image is determined by the number of protons (proton density), and modulated by the
how quickly the magnetization looses coherence (T2 relaxation) and relaxes back to
equilibrium (Ti relaxation) [102].

Specific patterns of radio frequency pulses and

gradients can be designed called pulse sequences to generate images that are proton
density, Ti or T2 weighted by modifying pulse sequence parameters called the repetition
time (TR), echo time (TE) and flip angle (a). More specifically, Ti or “spin-lattice”
relaxation and T2 or “spin-spin” relaxation occur simultaneously. Ti relaxation describes
the recovery of the net magnetization in the direction of the external magnetic field
direction (Bo). This relaxation is modeled by the equation:

Mz = Mz(o)[l-e(‘t/T1)] ,

Ti is time it takes for approximately 63% of the net magnetization to return to the
Bo direction. Usually, after a length of time equal to 5x T 1, the majority of the net
magnetization has recovered back to the initial state prior to excitation. T2 relaxation
describes the loss of the net magnetization in the transverse plane perpendicular to the
external magnetic field (Bo) [102], The T2 is the time when approximately 37% of the net
magnetization is still detectable in the transverse plane.
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Proton density (PD) images are acquired normally with a long repetition time and
a short echo time [102], The long repetition time reduces the Ti weighting while the
short echo time minimizes the T2 weighting. As a result, most of the tissues excited by
the radiofrequency pulse have more or less fully relaxed when the signal is measured.
Proton density images are much brighter than the corresponding Ti and T2 images
acquired using MRJ.
All three types of contrast are present to various degrees in an MR image.
However, depending on the anatomy that is to be examined, modifying the scan
parameters can emphasize each of the different types of contrast of the same tissue.
Similarly, some contrast agents are designed to be utilized in conjunction with images
acquire that emphasize a particular contrast. For example, we have developed a novel
Gd3+-DOTA-CAT contrast agent that is best suited for imaging using a Ti-weighted
acquisition. The gadolinium shortens the T 1 of the water surrounding the agent in which
it resides.

1.5.4

Paramagnetic Chemical Exchange Saturation Transfer (PARACEST)
Imaging
There are other ways to change signal intensity and contrast within MR images.

One such example is the use of frequency selective radio frequency pulses to selectively
excite specific pools of protons within a sample that then exchange with the bulk pool of
water that is measured. For example, one could selectively excite protons that are found
within cell membranes and normally not visible by MRJ. This method is usually called
magnetization transfer imaging. This idea can be extended into the realm of contrast
agents. For example, there exists a type of MRJ contrast agent that can generate contrast
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using this mechanism of Chemical Exchange Saturation Transfer (PARACEST) [103].
When a paramagnetic metal is included in the agent, the potential sensitivity increases
greatly and the agent is called a Paramagnetic CEST or PARACEST agent.
To understand how PARACEST agents work, we must consider two different
pools of water in a sample; the bulk or free water that we measure and a separate pool of
water bound to the PARACEST agent. Bound water refers to water molecules that are
bound or restricted, for instance, by momentarily interacting with contrast agents.
Because the bound water comes into close contact with the paramagnetic metal, its
Larmor frequency is shifted providing an opportunity to selectively excite this pool
without affecting the bulk water. The bound pool does however exchange with the bulk
pool, and by measuring the amount of magnetization that is transferred to the bulk pool,
we can observe the presence of the contrast agent. Several groups, including our own,
have demonstrated this ability using several types of lanthanide metals [104-107].

1.5.5

On-Resonance Paramagnetic Chemical Exchange Effect
A similar but more sensitive method of generating image contrast was described

by Vinogradov, et al. [108] called the On-resonance Paramagnetic Chemical Exchange
Effect or OPARACHEE. This method is conceptually similar to the PARACEST method
described above, but rather selective excitation of the bulk pool is used to generate
contrast in the presence of the contrast agent. In this method, the bulk magnetization is
perturbed in such a way that when there is no agent present, no change in signal intensity
is observed (effectively a 360 degree pulse is applied). However when a PARACEST
agent is present, spins that diffuse between the bulk pool and the bound pool do not
experience the full effect of the 360 degree pulse and therefore are not fully refocused
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leading to a decrease in image signal intensity.

The imaging technique has greater

sensitivity than the PARACEST imaging technique described above, but has several
limitations. The most significant limitation is that it is not possible to determine the
chemical shift of the bound water protons, therefore, this approach cannot be used to
relate signal changes to physiological properties of the sample which are normally
modulate chemical shift.

The OPARACHEE approach has been applied in-vivo to

visualize contrast agent within the kidneys of rats [109].

1.6

Molecular Biology

1.6.1

Cell Penetrating Peptides
Cell penetrating peptides (CPPs) are short peptides that facilitate cellular uptake

of various molecular cargo from small chemical molecules to nano-sized particles and
large fragments of DNA [110]. The cargo is associated with the peptides either through
chemical linkage via covalent bonds or through non-covalent interactions. CPPs typically
have an amino acid composition containing either a high relative abundance of positively
charged amino acids such as lysine or arginine, or have sequences that contain an
alternating pattern of polar/charged amino acids and non-polar, hydrophobic amino acids.
The main highlighting feature about these peptides is the huge diversity of the
transported molecules in terms of size and biological nature. For instance, the Tat peptide
has been used to internalize liposomes, adenovirus, plasmid DNA, peptide nucleic acids,
and paramagnetically labelled DOTA [111-117].

In addition to bringing targets

intracellularly, CPPs have demonstrated their in-vitro and in-vivo potential by entering
many cell types and tissues [118].
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CPPs hold great potential as in-vitro and in-vivo delivery vectors for use in
research and medicine.

Current use is limited by a lack of cell specificity in CPP

mediated cargo delivery and insufficient understanding of the modes of their uptake
[119]. In addition, fixation of cells on cover-slips or slides causing a re-distribution of
CPP and their cargo [120],

Therefore, experiments that involve CPP delivery must

include live imaging data while these contrast agents are being administered.
The first CPP was discovered independently by two laboratories in 1988 when it
was found that the trans-activating transcriptional activator (Tat) from Human
Immunodeficiency Virus 1 (HIV-1) could be efficiently taken up from the surrounding
media by numerous cell types in culture [121]. Since that time, the number of known
CPPs has expanded and small molecule synthetic analogues with more effective protein
transduction properties have been created. The first use of CPPs in crossing the blood
brain barrier was described by Schwarze et al., in which they reported a large protein able
to cross the BBB into significant areas of the brain [122, 123], Other studies describe
CPPs attached to therapeutic agents for delivery across the BBB that resulted in increased
drug efficacy [124, 125].
CPPs therefore provide a way to get the contrast agent across difficult barriers
such as the blood brain barrier. The next section will explain in better detail the principle
of how these agents could be targeted to accumulate in a diseased state.

1.6.2

Enzymatic Diffusion Trap of Contrast Agents
In normal control tissues, there exists a specific uptake and retention time of

contrast agents.

Uptake of contrast agents may depend on several factors including

molecular weight, charge at physiological pH, and lipophilicity to cross the blood-brain
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barrier and ability to be taken up into cells [126],

Similarly, the contrast agent

concentration within the tissue will eventually decrease as the agent leaves by diffusion,
export or through cell metabolism. It is difficult to discern which of the two events are
occurring, or whether they are occurring at the same time.
In diseased tissues there is often a change in the expression of specific proteins. In
the case of Alzheimer’s disease, there is an up-regulation of the lysosomal enzyme
cathepsin-D. With this increased expression, greater amounts of contrast agent would be
more likely to be recognized and cleaved by the protease cathepsin-D. Once the enzyme
has cleaved the contrast agent, the cell-penetrating peptide portion is removed leaving it
effectively trapped within the cell. In other words, the contrast agent would have a
greater difficulty leaving the cell as indicated by enzymatic trap.

1.6.3

Western Blotting
Protein analysis is a useful tool to evaluate expression levels within a biological

sample. For example, neuronal SN56 cells create an extensive number of proteins to
function on a normal basis. The ability to extract and study individual proteins could
provide valuable information in the cell line’s ability to grow, differentiate, and survive.
In our case, we examined cathepsin-D protein levels as a way to: a) confirm our cellular
transfection experiments, b) to support our hypothesis that increased cathepsin-D levels in
SN56 cells mimics our cellular model of AD.

In addition, we have extracted brain

samples of transgenic Alzheimer’s disease mice over one year old to quantify how much
cathepsin-D is being expressed.
Protein samples are obtained from either cell lysates or brain tissues for analysis.
Once each sample has been extracted and quantified, the same amount of protein would
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be prepared for each sample. Proteins are then denatured and then run by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Gel electrophoresis separates
the proteins by size and charge by applying an electric field through a gel medium. The
electric field attracts the overall charge on the molecule through the gel matrix. The gel
composition acts as a molecular sieve to slow down larger molecules and as a result, they
do not travel as far as smaller molecules. The combination of size and charge of a
molecule and the length of time that the electric field is applied will determine how much
separation occurs between the mixtures of proteins within a sample.

Once the

appropriately sized proteins have been separated, they are then transferred to a
nitrocellulose membrane where antibodies are able to easily bind to the proteins [127].
However, the nitrocellulose membrane must be blocked by milk or bovine serum albumin
to prevent excessive antibody binding. Primary antibodies are then added to bind to our
protein of interest. A wash occurs here with tris-glycine buffered tween-20 (TBST) to
remove excess primary antibody. Secondary antibodies are incubated afterwards to bind
to the primary antibodies.

A second wash occurs with TBST to remove the excess

secondary antibodies. The secondary antibodies react with a chemical solution to provide
signal which can then be detected using a multitude of techniques (i.e. x-ray film,
fluorescence). The amount of protein shown upon analysis depends on how thick and
dark the band appears. This information is utilized to quantify the amount of protein
being expressed by the cell lysate or tissue sample. An internal loading control is utilized
to measure how much protein exists by probing with actin or tubulin.
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Figure 1.3: Western Blot of Cathepsin-D expression in SN56 cells. The first lane was
loaded with a sample from non-transfected SN56 cells as a negative control. The next 6
lanes were loaded with 6-10 pg of Cat-D transfected SN56 cells. The smaller mature
form exists at 50 kDa, the larger immature form of Cat-D exists at 73 kDa. The
additional 27 kDa is from the mCherry fluorescent tag attached to the Cat-D protein.
Alpha tubulin is also shown underneath as a control.

1.6.5

Histology
Histology is the study of tissues and cells at the microscopic level. After the

injection of the dual-labeled contrast agents, the fluorescent properties of the contrast
agent can be evaluated. The ability to observe contrast agent at the cellular level is an
important technique so that we may evaluate its capability at crossing the blood brain
barrier, entering tissues, cells, and organelles. Post-injection of contrast agent, the mouse
is sacrificed after a set amount of time and then the brain is extracted and stored in 10%
neutral buffered formalin. A coronal section through the hippocampus of each mouse
was obtained in order to assess the amount of uptake within specific regions of the brain.

28

1.7

Preliminary Work on Cathepsin-D targeted contrast agents

The following section is a brief summary of the work that has been described in a
manuscript by: Suchy, M., Ta, R., et al. A paramagnetic chemical exchange-based MR1
probe metabolized by cathepsin D: design, synthesis and cellular uptake studies. 2010.
Organic & Biomolecular Chemistry. 8(11): p. 2560-6. As second author, I contributed to
performing the cellular uptake studies, metabolic cleavage experiments and wrote the
methods section for those experiments.

1.7.1 Contrast agent design and synthesis
The design of the novel MRI contrast agents was an idea that combined previous
works published in the literature and a need for the early diagnosis of AD. This work
described the synthesis and design of targeted contrast agents for cathepsin-D activity
[128], Preliminary studies examining enzymatic recognition and cellular uptake were
also performed. Figure 1.7 illustrates the molecular structure of the novel dual contrast
agent. The red portion shows how the lanthanide metal is placed within a DOTA cage,
where several different metals can be utilized depending on the type of MRI contrast
desired. The green part of the compound is where Oregon Green, a compound that
fluoresces when excited by the correct wavelength. The blue portion corresponds to
amino acid sequences which can be broken down into two sections. The first portion is
the cell-penetrating peptide (CPP) or TAT region.

This region was incorporated to

increase cellular uptake and help the contrast agent migrate across the blood brain barrier
with greater efficiency. The next portion is the cathepsin-D recognition site which allows
enzymatic targeting of the contrast agent. Thus, when the enzyme cathepsin-D interacts
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with the contrast agent it would cleave at the appropriate site also removing the cellpenetrating peptide. The remaining compound would consist of the MR and optical tags
for imaging in either modality.

PEPTIDE BACKBONE

Cell P*
Peptide

Optical Tag
(Oregon Green)
= Gd3+, Tm3+, etc.

Figure 1.4: Schematic diagram of cathepsin-D targeted contrast agent. The lanthanide
metal may be replaced depending on the type of desired MR contrast.

1.7.2

Enzymatic Recognition of Cathepsin-D Cleavage Domain
The first task in ensuring that the contrast agent was working effectively was to

evaluate its ability at being recognized by the enzyme cathepsin-D.

Studies were

performed that combined bovine cathepsin-D enzyme and Tm -DOTA-CAT. Samples
were incubated for 5 minutes in a buffer at a pH of 4.5, and then the addition of pepstatin
A was required to inhibit the enzymatic actions of cathepsin-D. The samples were then
sampled by electrospray-ionization mass spectrometry, which detects all molecular
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fragments and reports their respective sizes. Cathepsin-D cleaved the contrast agent
leaving a 1906 Da fragment size which corresponds to the following reaction:

Pre -Cleavage
T m 3*-DOTACAT

Post -Cleavage
Tm 3*-DOTACAT

Mass = 1906 Da
* Cleaved as predicted

Figure 1.5: Tm -DOTA-CAT reaction scheme illustrating cleavage by cathepsin-D
enzyme. The red boxes highlight the two phenylalanine amino acids (FF) that are cleaved
upon recognition by cathepsin-D as predicted.
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Figure 1.6: Deconvoluted electrospray-ionization mass spectrometry spectrum showing
the molecular mass of cleaved Tm3+-DOTA-CAT of 1906 Da. This molecular size
corresponds to the fragment without the cell-penetrating peptide region.
The size of the cleaved fragment was then examined using single mass analysis to
determine exactly where the cleavage had taken place within the cathepsin-D recognition
site.

The outcome demonstrated that cathepsin-D had cleaved Tm -DOTA-CAT

between two phenylalanine amino acid residues within the cleavage site.

The

experimental results were also verified and confirmed with other cathepsin-D cleavage
sites that have found the majority of product is cleaved within the two phenylalanine
amino acids.

1.7.3

Preliminary Cellular Uptake Experiments
'•> I

Early studies with the compound, Tm -DOTA-CAT, were performed to evaluate
the contrast agent’s ability to be taken up and retained in neuronal SN56 cells. It was
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found that after 30 minutes of incubation with the contrast agent, SN56 cells with up
regulated cathepsin-D retained a greater amount of the agent within the cell body. In
SN56 cells with a normal or basal amount of cathepsin-D expression, there was very little
to no contrast agent retained within the cell bodies. This indicated that there was a
selective uptake of contrast agent in cells over-expressing cathepsin-D. In addition, as the
concentration of the contrast agent increased, so did the retention of the agent over the
concentration range (5-100 pM).

Thus, neuronal SN56 cells exhibited selective and

concentration dependent retention of Tm3+-DOTA-CAT.

DIC

Cathepsin-D

Tm^-DOTA-CAT

Overlay

Figure 1.7: Panels A-D illustrates SN56 neuronal cells transfected with human cathepsinD. The first set of panels (a and e) is the DIC image of SN56 cells. The second column
of images (c and f) displays the fluorescence coming from the red channel. The third set
of panels (c and g) show fluorescence obtained from the green channel. Lastly, the fourth
panel (d and h) demonstrates the overlay of both red and green channels. The bottom row
of images (e-h) are control SN56 cells.
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1.7.4

OPARACHEE Detection of Tm3+-DOTA-CAT
In addition to fluorescence studies of the contrast agent Tm3+-DOTA-CAT, we

wanted to demonstrate its detection in the MRI environment. A 3 mM Tm3+-DOTA-CAT
solution was prepared by dissolving in water and acetonitrile. Three types of solutions
were prepared: 1) control with 80% water and 20% acetonitrile, 2) DOTA-CAT agent,
not including the Tm3+ lanthanide metal, and 3) the Tm3+-DOTA-CAT compound after
Cat-D cleavage.

The prepared samples were then detected using on-resonance

paramagnetic chemical exchange effect (OPARACHEE) in the 9.4T MRI scanner.
The results shown in Figure 1.11 illustrate the detection of our contrast agent in
the MRI environment. The scale on the right hand side of the images demonstrates the
signal intensity of each sample after a particular pulse sequence has been applied. The
first row of samples shows the control FLASH images. The second row of samples show
a WALTZ-16 prep image acquisition that shows a signal decrease as expected that is
more pronounced in the third column that contains the Tm

metal.

The last row

illustrates the signal intensity difference between the control FLASH and Waltz-16
image.

The final result was a 24% OPARACHEE contrast from the compound
T i

containing the Tm metal compared to both controls.
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Figure 1.8: OPARACHEE contrast generated by Tm3f-DOTA-CAT.

To summarize, we studied the properties of the MRI, fluorescent, Cat-D
recognition, and cell-penetrating peptide properties designed for our dual MRI/fluorescent
probe. Enzymatic degradation studies revealed that Tmu - DOTA-CAT was a substrate
for Cat-D, where mass spectrometry studies confirmed cleavage between the two
phenylalanine residues. Fluorescence-based studies demonstrated selective intracellular
uptake in cells that over-expressed Cat-D. The cleavage of the protease domain removes
the CPP allowing the probe to accumulate within cells increasing the retention time.
Lastly, in-vitro MRI contrast was achieved using the OPARACHEE method.

These
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preliminary results demonstrate the potential utility of this MRI/fluorescent contrast
agent.

1.8

Summary
This chapter discussed the wide range of chemical and biological applications that

exist for MR1 contrast agents. Contrast agent enhanced MRI could become an invaluable
tool for the diagnosis of Alzheimer’s disease and many other conditions.

The

development of molecular imaging may also have specific application to drug
development in animal models of disease. With improved targeted delivery of these
agents, the ability to diagnose diseases will become more sensitive, precise, and objective.
Finally, contrast agents that detect biological phenomena by altering the intensity of
signal enhancement in a conditional fashion are steps toward unravelling the complexity
of biological systems. Further, these agents represent the introduction to complete, noninvasive, medical examinations that are safe, fast, and accurate.

1.8.1

Scope of Thesis
The testing and development of advanced MRI contrast agents is the focus of this

thesis. Clinically used contrast agents aid in the visualization of the extracellular space or
blood pool in MRI. To extend the usefulness of these contrast agents, the chemistry was
modified to develop agents that are sensitive to biological events and directed to cellular
targets. These two improvements are closely related in that many biologically significant
molecules are located in specific parts of the body, cell, or tissue. An introduction into
Alzheimer’s disease, the field of MRI, fluorescence imaging, and contrast agents is
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presented in Chapter 1 along with a preliminary description of our developing contrast
agent.

Chapter 1 proceeds to outline previous literature attempts at target-specific

delivery of contrast agents and the development of biologically sensitive contrast agents.
Chapter 2 will describe further characterization and testing of contrast agents in cell
culture and in-vivo. This work was taken from the manuscript submitted to Contrast
Media and Molecular Imaging entitled, A Dual Magnetic Resonance Imaging (MRI) /
Fluorescence Contrast Agent for Cathepsin-D Detection. The final chapter will provide a
framework for future studies and the upcoming role of contrast agents in AD.
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Chapter 2: A Dual Magnetic Resonance Imaging/Fluorescent
Contrast Agent for Cathepsin-D Detection1

2.1

Introduction
Alzheimer disease (AD) is the most common neurodegenerative disease in adults

and afflicts 17 million people worldwide [1], Currently, there is no approved biomarker
available for early detection and diagnosis must be made clinically once symptoms are
apparent [2, 3], However, the pathological changes of AD are believed to begin more
than a decade before the development of symptoms, and irreversible damage may already
be present at the time of diagnosis [4], Therefore, validated biomarkers to objectively
screen for pre-clinical AD are critically needed.
One potential early marker for AD is Cathepsin-D (Cat-D), a ubiquitously
expressed aspartic protease [5, 6], Cat-D is a protease that resides in lysosomes, which
are specialized sub-cellular compartments responsible for the degradation of proteins,
lipids and carbohydrates. Proliferation of lysosomes has been reported to be one of the
earliest histopathological changes in AD, occurring before the appearance of classical
neuropathological changes such as amyloid plaque deposition [7]. This proliferation is
accompanied by massive upregulation of lysosomal enzymes including Cat-D such that
with advancing disease, Cat-D staining eventually fills neurons [8], Amyloid plaques
also contain high levels of biochemically active lysosomal enzymes including Cathepsins
B and D [9-11], Cat-D has been shown to be upregulated in the cerebrospinal fluid of
subjects with AD [12], in subjects with Familial AD mutations, and in mouse models of
AD [13-15]. A sa result, Cat-D may be an excellent target for the early detection of AD.
1 A version of Chapter 2 was submitted to Contrast Media and Molecular Imaging on September 7th, 2011
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Although many other imaging modalities exist, in-vivo imaging of protease
activity by magnetic resonance imaging (MRI) would provide the widest potential clinical
benefit due to the wide spread use of MRI scanners. MRI does not expose patients to
radiation, and would allow the detected contrast to be imaged and automatically
registered with the in-vivo anatomical, functional, and chemical information accessible by
MRI [16-18],
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Figure 2.1: Molecular structure of Gd3 -DOTA-CAT and Tm3 -DOTA-CAT. An
imaging moiety consisting of a metal chelator (with Gd or Tm lanthanide metal) for
MRI detection (red) and an Oregon Green (green) fluorescent tag for optical detection.
This is coupled to a peptide backbone consisting of a cathepsin-D cleavage sequence and
a cell-penetrating peptide sequence.

We have previously reported the synthesis of a dual MRI/fluorescent contrast
agent for the detection of Cat-D activity [19] (Figure 2.1). This compound consists of an
Oi

MR imaging moiety that includes a caged lanthanide metal, such as Gd to produce Tiweighted MRI contrast or Tm

to produce MRI contrast by PARAmagnetic Chemical
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Exchange Saturation Transfer (PARACEST) [20, 21]. Oregon Green is also incorporated
for optical detection [22], These imaging moieties are conjugated to a peptide backbone
containing a Cat-D cleavage site and a Tat sequence derived from the HIV virus that
enhances penetration through cell membranes and across the blood brain barrier (BBB)
[23], In this strategy, the Tat peptide facilitates transport of the entire molecule across the
BBB both into and out of the central nervous system. In the presence of elevated levels
of Cat-D, cleavage of the agent at the Cat-D cleavage site will release the Tat peptide,
trapping the MR visible/Oregon Green components inside the BBB or cell [19]. This
approach to contrast agent design is similar to the strategy proposed by Roger Tsien’s
group in conjunction with optical labels and is conceptually similar to the process used in
Positron Emission Tomography (PET) imaging that allows flourodeoxyglucose (FDG) to
accumulate in cells as FDG-6-P. One major advantage of this method is that a single CatD molecule can cleave multiple contrast agent molecules leading to accumulation of the
contrast agent inside the BBB or cell, with a resulting amplification of the observed
signal.
We have previously demonstrated that Tm -DOTA-CAT is a substrate for Cat-D
and it is taken up and retained by cells over-expressing Cat-D [19]. Although Tm DOTA-CAT can be detected using the On-resonance PARAmagnetic Chemical Exchange
Effect (OPARACHEE) [24], the inclusion of Gd3+ in the agent may increase in-vivo
detection sensitivity using Ti-weighted MR imaging. The purpose of the current study
was to determine the minimum concentrations required for optical and MR detection, and
establish the time course of cellular uptake and retention in the brain in normal mice and
mouse models of Alzheimer’s disease.
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2.2

Methods

2.2.1

Magnetic Resonance Imaging
To study the Tj effect of agent concentration on image contrast, a series of 10%

(w/v) heat-treated (samples heated in an 80 °C water bath for 10 minutes) Bovine Serum
Albumin (BSA; Sigma Aldrich, St. Louis, MO) tissue phantoms containing a range of
I

Gd -DOTA-CAT concentrations (0-500 pM) were prepared as in [25]. This agent was
ni

compared to the standard and widely used contrast agent Gd -DTPA (Bayer Healthcare
Pharmaceuticals Inc., Germany) in 10% BSA as above.

Ti-weighted images of the

phantoms were acquired on a 9.4 Tesla small animal MRI scanner (Agilent, Palo Alto,
CA) using a spin-echo Ti-weighted pulse sequence (field of view = 38.4 x 38.4 mm , data
matrix: 192 x 192, repetition time = 50 ms, echo time = 14 ms, 2 averages, 2 dummy
scans, 200 pm resolution) at 37°C. The T| time constants were measured using an
inversion prepared spin-echo multi slice pulse sequence (TE = 14 ms, TR = 50 ms, TI =
0, 10, 20, 40, 80, 160, 320, 640, 1280, 2500 ms, 2 averages, 2 dummy scans). The Ti
time constant of each solution was measured by fitting a single exponential curve to the
signal intensity as a function of the inversion times (TI). The inverse of the longitudinal
relaxation time (Ri = 1 / Ti) was plotted against concentration and fit to a straight line to
estimate the relaxivity.

2.2.2

Detection Limit of Tm3+-DOTA-CAT and Gd3+-DOTA-CAT by Optical
Imaging
To determine the emission peak, emission spectra were obtained at 5 nm intervals

for samples of 50 pM FITC-dextran (Sigma Aldrich, St. Louis, MO), 1 mM Tm3+-
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DOTA-CAT, and 1 mM Gd3+-DOTA-CAT excited at 488 nm. Serial dilutions of both
compounds were performed to create a range of concentrations (1 nM - 10 pM). All
samples were prepared in a 96-well black plate (Coming Costar, Lowell, MA) in
triplicate, sampled by SpectraMax5 (Molecular Devices, Sunnyvale, CA) and analyzed by
SoftMax Pro data analysis software (Molecular Devices, Sunnyvale, CA).

2.2.3

Cell Culture
SN56 cells were a gift from Dr. Jane Rylett (The University of Western Ontario).

SN56 cells were derived from septum neurons (Septal neurons X neuroblastoma
N18TG2) [26] and present a number of neuronal features including expression of synaptic
vesicle proteins [27] and neuronal type calcium channels. These features are increased by
differentiation [28, 29], Cells were maintained in Dulbecco's modified Eagle's medium
(Gibco)

supplemented

with

5%

fetal

bovine

semm

(HyClone)

and

1%

penicillin/streptomycin (Gibco). Cell differentiation was performed with the addition of 1
mM dibutyryl-cyclic AMP in the same medium without fetal bovine semm for 24 hours.
Transient transfections were performed with plasmid expressing a Cat-D-mCherry fusion
protein using Lipofectamine 2000 Reagent (Invitrogen) according to manufacturer's
instructions as previously described [30],

2.2.4

Cellular Uptake and Confocal Microscopy
SN56 cells were grown in 35-mm glass-bottomed culture dishes (MatTek

Corporation, Ashland, MA). SN56 cells were incubated at 37 °C for 30 minutes with 50
i I

pM Tm -DOTA-CAT added to cell culture media. Cells were washed three times with
hanks buffered saline solution (HBSS; Invitrogen) and imaged using a Zeiss LSM 510-
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Meta laser-scanning confocal microscope (Carl Zeiss, Germany) using a 63X 1.4
numerical aperture oil immersion lens. The contrast agent was visualized using a 488 nm
excitation laser and a 500-530-nm emission band pass filter set. Red fluorescence from
the Cat-D-mCherry fusion protein was imaged using a 543 nm excitation laser and long
pass 560 filter set. Uptake was quantified by counting the number of cells that had
clearly taken up green fluorescent Tm -DOTA-CAT by an observer blinded to their CatD expression.

At least 277 cells were counted from three independent uptake

experiments.

2.2.5 Western Blotting and Antibodies
All cell and tissue lysates were prepared using protease cocktail inhibitors (Roche,
Mississauga, ON) with pepstatin A. Lanes were run with 20 pg of protein on a 12%
SDS-polyarcylamide gel and the resolved proteins were semi-dry transferred to a
nitrocellulose membrane (Bio-Rad, Mississauga, ON) using a Trans-Blot® Semi-Dry
Electrophoretic Transfer Cell (Bio-Rad, Mississauga, ON). The membrane was soaked
with 5% non-fat milk (w/v) dissolved in tris-glycine buffered saline tween-20 (0.05%
TBST) to block free protein binding sites. Blots were probed using Anti-Cat-D antibody
(Santa Cruz Biotechnology, Santa Cruz, CA), and detected using rabbit-anti-goat coupled
to horseradish peroxidase using enhanced chemiluminescence and exposed to CLXposure film (Thermo Scientific). Blots were re-probed with anti-Alpha-tubulin (Sigma
Aldrich, St. Louis, MO) as a loading control. Since immature Cat-D is also the active
form and performs the same enzymatic functions as the mature form, both forms were
grouped into a total Cat-D expression [5], Films were scanned and quantified using
ImageJ (http ://rsbweb .nih.gov/ij /).
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2.2.6

Cell Viability Studies
SN56 cells were seeded in 12-well plates and incubated overnight before

treatment of 50 pM Tm3+-DOTA-CAT. Following the indicated incubation time (0, 2, 4,
6, 24 hrs), cell density and viability were determined by 0.4% trypan blue exclusion in
triplicate. Light microscope images were acquired (lOx lens) in 5 random areas within a
well and cell counting was performed.

2.2.7

Mice
All animal studies were conducted in accordance with the guidelines of the

Subcommittee on Animal Care at the University of Western Ontario, and conformed to
the Canadian Council on Animal Care guide for the care and use of laboratory animals.
One year old APP-Swedish/PSl-dE9 transgenic Alzheimer’s disease mice (Jackson
Laboratories, Bar Harbour, ME) and age-matched controls BL/6 (Jackson Laboratories,
Bar Harbour, ME) were a gift from Dr. Marco A.M. Prado and Vania Prado (The
University of Western Ontario).
mouse/human

amyloid

These double transgenic mice express a chimeric

precursor

protein

bearing

a

Swedish

mutation

(Mo/HuAPP695swe) and a mutant human presenilin 1 with a deletion in exon 9 (PS1dE9) and develop amyloid plaques after the age of 6 months [31].

2.2.8

Contrast Agent Uptake in PSl-dE9 and Control Mouse Brain Tissues
Mice were anaesthetized with 4% isofluorane and oxygen (1 L/min). A tail-vein

catheter was established and a saline flush was performed to ensure the catheter was
accurately placed. Mice were injected intravenously with 100 pL of 1 mM Tm -DOTACAT over four minutes using a Harvard Apparatus PHD 2000 programmable pump
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(Instech Laboratories, Plymouth Meeting, PA). Post-injection, mice were sacrificed at 30
minutes (n = 3), 60 minutes (n = 3), 120 minutes (n = 3) and the brain was extracted. The
prefrontal cortex was removed, placed on dry ice and stored at -80°C for western blotting.
The rest of the brain was fixed in 10% neutral buffered formalin for at least 48 hours.

2.2.9

Histological Analysis of Transgenic PSl-dE9 and Control Mice
Mouse brains were paraffin embedded and sectioned into 5 pM thick coronal

sections. To detect Cat-D, sections were processed using a 2100 Retriever (Pick Cell
Laboratories, Lelystad, Netherlands) and stained with antibodies against Cat-D (Santa
Cruz Biotechnology, Santa Cruz, CA). Antibodies were detected using an AlexaFluor
543 (red) anti-rabbit secondary for immunofluorescence (Molecular Probes) and nuclei
were counterstained with DAPI (Sigma-Aldrich, St. Louis, MO). Sections were imaged
by confocal microscopy on a Zeiss LSM 510 META laser-scanning confocal microscope
(Carl Zeiss, Germany) using a 63X 1.4 numerical aperture oil immersion lens. The
contrast agent was visualized using a 488 nm excitation laser and a 500-530-nm emission
band pass filter set. Red fluorescence from Cat-D was imaged using a 543 nm excitation
laser and long pass 560 filter set. Blue fluorescence from DAPI staining was imaged
using a 2-photon Chameleon excitation laser at 750 nm and 390-465 nm emission band
pass filter set. Because the green contrast agent signal was quite diffuse, the confocal
slice thickness was increased to 10 microns. Mean pixel intensity was analyzed across
the

image

for

each

time

point

using

Photoshop

(Adobe)

and

ImageJ

(http://rsbweb.nih.gov/ij/). Mean pixel intensity levels were assigned to each group and
their respective time points expressed as mean ± SEM. Each set of images were acquired
on the same day and with identical acquisition settings.
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To examine the uptake within the cortex, CA1, and CA3 regions of the
hippocampus, non-injected mean pixel intensity values were subtracted from controlinjected and PSl-dE9 injected mean pixel intensity values. Two-tailed paired t-tests were
performed using Prism5, (GraphPad, La Jolla, CA) to compare the mean pixel intensity in
images between control-injected and PSl-dE9 injected mice at each time point (p < 0.05).

2.3

Results

2.3.1 In-Vitro MRI: Ti Relaxivity of Gd3+-DOTA-CAT
We examined the relative Ti-weighted signal intensities from phantoms
containing a range of concentrations of Gd3+-DOTA-CAT and conventional Gd3+-DTPA
in 10% bovine serum albumin at 9.4T at 37°C (Figure 2.2A). Both agents showed a
concentration-dependent increase in Ti signal intensity with Gd3+-DOTA-CAT generating
higher signals than Gd3+-DTPA, indicating more efficient Ti relaxation with this agent.
The Ti relaxation time constant of each compound at concentrations ranging from 50 pM
to 500 pM were studied.

Gd3+-DOTA-CAT had a lower Ti time constant at each

concentration compared to Gd3+-DTPA. Plotting the relaxation rate (Ri = 1 / Ti) as a
function of concentration (Figure 2.2B), Gd3+-DOTA-CAT had a relaxivity of 6.9
(mM-s)"1 compared to 3.2 (mM-s)'1 for Gd3+-DTPA at 9.4 Tesla. The R2 of the slopes
were 0.99 and 0.98 for Gd3+-DTPA and Gd3+-DOTA-CAT respectively.
♦

I

The 95%

confidence intervals for the slope of Gd -DTPA was between 2.7 and 3.6 (mM-s)

1

compared to the slope for Gd -DOTA-CAT, which was between 4.5 and 9.3 (mM-s) .
Therefore, Gd3+-DOTA-CAT is expected to generate greater signal changes in Tiweighted MRI than commercially available Gd3+-DTPA at 9.4 Tesla.
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Figure 2.2: In-Vitro MRI of Gd3+-DOTA-CAT. Spin Echo Multi Slice (SEMS) Tlweighted image of various concentrations of Gd3+-DTPA and Gd3+-DOTA-CAT in 10%
BSA, and 10% BSA alone acquired at 37°C at 9.4T. Echo time = 14 ms, repetition time =
50 ms, 2 averages, 2 dummy scans, 200 pm resolution. (B) Relaxation rate (Ri = 1/Ti)
as a function of concentration. Linear best fitted curves are displayed. Gd3+-DOTA-CAT
has a greater relaxivity 6.9 (mM-s)"1than clinically used Gd3+-DTPA.

2.3.2

Fluorescence Detection of Tm3+-DOTA-CAT and Gd3+-DOTA-CAT
To examine the fluorescent characteristics of the agents, we generated

fluorescence intensity curves of Tm3+-DOTA-CAT and Gd3+-DOTA-CAT plotted against
their concentrations (Figure 2.3A). FITC-dextran was included as a control. The peak
emission for FITC-dextran, Tm3+-DOTA-CAT and Gd3+-DOTA-CAT was 525 nm (data
not shown). Both Tnr3+-DOTA-CAT and Gd3+-DOTA-CAT were clearly detectable at 1
nM concentration. There was a significant difference between the blank control and each
concentration of Tnv3+-DOTA-CAT (p < 0.05). Figure 2.3B shows an expanded scale in
the nanomolar range of both agents. As expected, FITC-dextran exhibited greater
fluorescence intensity than Tm3+-DOTA-CAT and Gd3+-DOTA-CAT, reflecting the
higher molar concentration of fluorophore in FITC-dextran.
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» FITC-Dextran
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Figure 2.3A: Fluorescent detection of Tm3+-DOTA-CAT and Gd3+-DOTA-CAT. (A)
Fluorescence intensity of FITC-Dextran, Tm3+-DOTA-CAT and Gd3+-DOTA-CAT was
determined in the concentration range of 1 nM to 10 ¡aM. FITC-Dextran, Tm3+-DOTACAT and Gd3+-DOTA-CAT data were fitted to a polynomial function. There are six data
points for both agents.
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Figure 2.3B: Expanded scale of the plots shown in Figure 2.3A demonstrating detection
of concentrations down to 1 nM. All data points were measure in triplicate and displayed
as mean ± SD.
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2.3.3

Cellular Uptake of Tm3+-DOTA-CAT
We have previously demonstrated that Tm3+-DOTA-CAT is taken up and retained

by SN56 cells over-expressing Cat-D [19]. Figure 2.4A shows the quantified uptake in
cells over-expressing Cat-D. We counted the number of cells that demonstrated uptake
compared with non-transfected cells. In these uptake experiments, 19% ± 2.0% of cells
exposed to the agent at 5 pM took up Tm3+-DOTA-CAT, and this number increased with
concentration so that at 100 pM, 78% ± 6.5% of cells took up and retained the agent. In
contrast, a maximum of 4.7% ± 1.3% of cells not over-expressing Cat-D retained the
agent over the entire concentration range. This difference between non-transfected and
transfected SN56 cells is statistically significant at each concentration (p < 0.05).
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Contrast Agent Concentration (fxM)

B

Time (Hours)

Figure 2.4: (A) Cellular uptake and retention of Tm -DOTA-CAT was observed in a
concentration dependent manner in cells over-expressing Cat-D-mCherry. Cell counting
was performed to compare the percentage of transfected SN56 cells taking up Tm3+DOTA-CAT versus non-transfected cells retaining Tm3+-DOTA-CAT at various
concentrations after 30 minutes of incubation. The asterisk indicates statistical
significance at each time point (p < 0.05). Error bars represent standard error of the mean.
(B) Cell counting was performed on the light microscopy images of SN56 cells incubated
with Tm3+-DOTA-CAT for 2, 4, 6, and 24 hours with trypan blue (n = 3). There were no
statistically significant differences in cell survival between any of the time points.
2.3.4

SN56 Neuronal Cell Viability Studies
For a preliminary assessment of the toxicity of this compound, we exposed SN56

cells in culture to 50 pM of Tm3+-DOTA-CAT for 2, 4, 6, and 24 hours and stained them
with trypan blue to identify dead cells. Figure 2.4B shows that at 2, 4, 6, and 24 hours,
88% ± 4.1%, 88% ± 3.6%, 86% ± 3.6%, and 90% ± 6.7% of SN56 cells, respectively,
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were viable.

Control cells were left in culture medium for 24 hours. There was no

significant difference between the percentage of cells surviving in control SN56 cells and
SN56 cells exposed to Tm3+-DOTA-CAT up to 24 hours.

2.3.5

Western Blotting of Cathepsin-D
We examined the levels of cathepsin-D in control-injected and PSl-dE9 mice by

western blotting. These blots were then quantified and normalized for protein loading
using the structural protein alpha tubulin as a loading control (Figure 2.55A). In control
and PSl-dE9 mice, Cat-D was expressed in an intermediate or immature (46 kDa) and
mature form (33 kDa). Total Cat-D expression was collected from both immature and
mature forms of Cat-D expression. Mean relative density ± SEM was calculated for each
of the following groups: 45 day old controls (0.92 ± 0.02), 45 day old PSl-dE9 (0.98 ±
0.02), 1 year old controls (1.28 ± 0.08), 1 year old PSl-dE9 (1.40 ± 0.11). There were
significant differences between 45 day old controls and 1 year old controls (t[4.49], p <
0.01) and between 45 day old PSl-dE9 and 1 year old PSl-dE9 mice (t[3.89], p < 0.05).
Although there appeared to be slightly more Cat-D in the 1 year old PSl-dE9 mice than
the control mice after normalization, this difference was not significant.
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Figure 2.5: (A) Representative western blot of the immature and mature forms of
cathepsin-D. All lanes were loaded with 20 pg of protein. The blot was re-probed with
alpha tubulin as a loading control. (B) Quantification of total cathepsin-D expression
levels in 45 day old controls and PSl-dE9 mice and 1 year old controls and PSl-dE9
mice. Band intensities were quantified and normalized for loading using alpha tubulin.
Data represent mean ± SD from at least 3 individual mice. There were significant
differences between the expression of 45 day old controls and 1 year old controls, 45 day
old PSl-dE9 and 1 year old PSl-dE9, and between 45 day old PSl-dE9 and 1 year old
controls (p < 0.05).

63

2.3.6

Contrast Agent Uptake in the Cortical PSl-dE9 and Control Mouse Brain
Figure 2.6 illustrates contrast agent uptake and retention within the cortex

immediately dorsal to the hippocampus of both 1 year old control and 1 year old PSl-dE9
mice at 30 minutes post-injection. There was substantial Cat-D staining in both controls
and PS 1-dE9 sections and there was no clear difference between these two groups. Red
blood cells (RBCs) within blood vessels were autofluorescent in both the green and red
channels and appeared very bright in these images.

The contrast agent was able to

penetrate the blood brain barrier to transverse into the neuropil as well as into cells
containing Cat-D.

Tm^-DOTA-CAT

Cathepsm-D

DAPI

Overlay

Non-lnjected Control

Control Injected 30 Minutes

PS1-dE9 Injected 30 Minutes

Figure 2.6: Representative confocal microscopy images of the cerebral cortex in 1 year
old control and 1 year old transgenic PSl-dE9 mice. The first column illustrates the
amount of fluorescent signal coming from the green channel (autofluorescence and Tm DOTA-CAT). The second column of images displays the cathepsin-D staining in red.
DAPI nuclear staining is shown in blue and the overlay of all channels in the last column.
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Each representative confocal image from the cortex was acquired to cover an area
of 101,250 pm from two sections, performed in triplicate in three control and three PS1dE9 mice at each time point (Figure 2.7A). The mean pixel intensity of the green channel
was determined for each image using ImageJ software and these were averaged for all of
the images at each time point (Figure 2.7B). Non-injected mice had the lowest mean
pixel intensity value 70 ± 0.3 fluorescence units. These non-injected fluorescence values
were subtracted from the fluorescence units obtained for control and PSl-dE9 injected
mice at each time point. Control mice exhibited substantial green signal at 30 minutes,
785 ± 88 fluorescence units which declined over time to 220.3 ± 68 fluorescence units
and eventually to 2.7 ± 2.7 fluorescence units at 120 minutes (Figure 2.7B). In contrast,
PSl-dE9 mice demonstrated increased green signal from 30 minutes at 295 ± 11
fluorescence units which rose to 410 ± 69 fluorescence units at 60 minutes before
dropping to 89 ± 14 fluorescence units at 120 minutes. A two-tailed paired t-test was
conducted to compare the mean fluorescence levels across images in control-injected, and
PSl-dE9 injected mice at each time point. There was a significant difference between the
mean fluorescence of control and PSl-dE9 mice at 30 minutes (p < 0.05) and 120 minutes
(p < 0.05).
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Figure 2.7: Quantitative uptake and retention of contrast agent in control and PSl-dE9
cortex of the brain. (A) Normal and PSl-dE9 mice received IV injections of contrast
agent and were sacrificed at the indicated time point. Coronal sections were taken from
each brain and representative images showing contrast agent (green) in cortex directly
dorsal to the hippocampus. (B) Mean pixel intensity (± SEM) of the green channel was
measured across whole images. Control injected mice exhibited the greatest amount of
uptake and retention at 30 minutes and returned to non-injected levels of fluorescence by
120 minutes. PSl-dE9 mice showed a slower uptake of contrast agent, peaking at 60
minutes and demonstrated a longer period of retention of agent by 120 minutes. The
asterisks represent a statistical significance of p < 0.05.
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2.3.7

Contrast Agent Uptake in PSl-dE9 and Control CA1 and CA3 Hippocampus
Since the hippocampus is affected early in human AD, we examined the uptake

and retention of our agent in the CA1 and CA3 regions of the hippocampus of noninjected, control, and PSl-dE9 injected mice. This analysis was performed using at least
three images covering 101,250 pm from at least two sections performed in triplicate
acquired in the CA1 and CA3 regions of control and PSl-dE9 mice at each time point.
Non-injected mice had a mean fluorescence level of 927 ± 26 fluorescence units (CA 1)
and 902 ± 23 fluorescence units (CA 3) (data not shown).

These non-injected

fluorescence values were subtracted from the fluorescence units obtained for control and
PSl-dE9 injected mice at each time point. Figure 2.8 demonstrates that all injected mice
exhibited greater fluorescence levels in the CA1 and CA3 regions than in non-injected
mice.

In the CA1 region of the hippocampus, control-injected mice had a mean

fluorescence level of 197 ± 47 at 30 minutes, 163 ± 39 at 60 minutes, and 75 ± 17
fluorescence units at 120 minutes. PSl-dE9 injected mice had a mean fluorescence level
of 68 ± 20 at 30 minutes, 154 ± 28 at 60 minutes, and 122 ± 26 fluorescence units at 120
minutes. The control-injected mice displayed the greatest amount of fluorescence at the
30 minute time point and gradually declined over time. In contrast PSl-dE9 injected
mice showed an increasing amount of fluorescence from 30 minutes to 60 minutes and
then an eventual decline at 120 minutes. Between groups, control-injected mice had
greater tissue fluorescence than PSl-dE9 injected mice at 30 minutes (p < 0.05) and a
trend towards higher fluorescence at 120 minutes. Within groups, the control mice had
greater fluorescence at 30 minutes compared to 60 minutes and 120 minutes, and greater
fluorescence at 60 minutes compared to 120 minutes (p < 0.05). The PSl-dE9 mice had
greater fluorescence at 60 minutes compared to 30 minutes (p < 0.05).
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In the CA3 region, both control and in PSl-dE9 injected mice displayed a similar
pattern of contrast agent uptake to that observed in the CA1 hippocampus region. Control
injected mice had a mean fluorescence level of 215 ± 25 at 30 minutes, 202 ± 36 at 60
minutes, and 106 ± 23 fluorescence units 120 minutes. PSl-dE9 injected mice had a
mean fluorescence level of 103 ± 30 at 30 minutes, 152 ± 32 at 60 minutes, 140 ±51
fluorescence units at 120 minutes. Between groups, control-injected mice had greater
fluorescence than PSl-dE9 injected mice at 30 minutes (p < 0.05). Within groups,
control had greater fluorescence at 30 minutes and 60 minutes compared to 120 minutes
(p < 0.05).
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CA 1 Hippocampus

CA 3 Hippocampus

Control
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Figure 2.8: CA1 (A) and CA3 (B) hippocampal mean pixel intensities in control and
PSl-dE9 at various time points. Control injected mice had the greatest amount of uptake
and retention at 30 minutes and then decreasing fluorescence over time in both regions of
the hippocampus. PSl-dE9 injected mice exhibited a delayed uptake with peak
fluorescence levels at 60 minutes with washout occurring at 120 minutes. Similar uptake
patterns were observed in both the CA1 and CA3 regions of the hippocampus as
compared to that observed in the cortex. There was a significant difference in the uptake
and retention of Tm3+-DOTA-CAT between control-injected and PSl-dE9-injected mice
in the CA1 and CA3 regions of the hippocampus at 30 minutes. The asterisks represent a
statistical significance of p < 0.05.
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2.4

Discussion
In the current study, a strategy is presented to diagnose AD that may be useful at

the earliest stages of the disease. This strategy is based on the observation that the
upregulation of lysosomes and lysosome related organelles and enzymes are a very early
event in AD. The goal of this study was to demonstrate the tissue uptake and retention of
a novel type of MRI contrast agent based on the activity of the lysosomal enzyme
cathepsin-D. Here we present two variations of the contrast agent and demonstrate that
these agents can be detected experimentally using both MRI and optical imaging
techniques. Specifically, we demonstrated detection of Gd -DOTA-CAT by MRI in a
concentration range from 50-500 pM, where it exhibited greater sensitivity than clinically
used Gd3+-DTPA at 9.4 Tesla. The experimentally observed relaxivity for Gd3+-DTPA
was also verified in similar in-vitro studies [32, 33], Previously, Tm3+-DOTA-CAT was
also detected by MRI using OPARACHEE contrast at 0.5-4 mM concentrations at 9.4
Tesla [19]. In the current study, in-vitro cellular uptake studies demonstrated that Tm3+DOTA-CAT was taken up and retained by SN56 neuronal cells over-expressing Cat-D in
a concentration dependant manner with minimal toxicity.

We also studied the time

course of uptake and retention in aged normal and AD-mice within the cortex, CA1 and
CA3 regions. The time course of uptake and retention of the fluorescent agent was
clearly different in the AD and control mice and would allow the differentiation of these
two groups of mice.
Unfortunately the mouse line we selected for the study did not express elevated
levels of Cat-D compared to control mice. This result may have occurred because the
wrong ages were chosen to study these mice; Cat-D levels did rise with age in the control
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and AD mice strains, and it is likely that Cat-D would rise in the AD mice before the
control mice. Therefore, determining the time course for increased Cat-D expression in
this mouse line will be completed in future work. Another possibility is that if Cat-D
were bound up in insoluble amyloid plaques, it might have been underestimated in
western blots or immunostaining, as it normally requires harsh organic solvents to recover
insoluble material from amyloid plaques. Finally, we note that there is considerable
strain to strain variation in pathology in AD mice, and these mice may simply not over
express high levels of Cat-D and future studies will assess other transgenic mouse lines
have greater over-expression.
It is not immediately clear why the newly synthesized Cat-D-targeted agent
presented in this work was able to distinguish the AD and control mice despite these mice
having similar levels of Cat-D. One possible explanation is that the Cat-D in AD mice
might be distributed differently than that found in control mice. For example, Cat-D may
be present more in the extracellular space allowing easier access to the agent. Another
possibility is that there may be an alteration in the rate of transit of this agent across the
blood brain barrier in AD mice. Future studies will need to address the importance of the
Cat-D interaction and cleavage in producing these signal differences.
Currently, the leading candidates for diagnostic use in AD are amyloid binding
compounds such as the Pittsburgh B (PIB) [34] compound and florbetapir [35], These
compounds bind to [3-amyloid aggregates in the brain and are detected using Positron
Emission Tomography (PET). Whether PIB or florbetapir-PET imaging constitute as
good biomarkers for AD also depends on whether P-amyloid burden in the brain is indeed
the earliest or best pathology on which to focus. Currently, the diagnostic use of these
agents is limited by substantial overlap in signals between controls, subjects with mild
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AD/Mild Cognitive impairment, and AD [36-39]. In other words some AD patients do
not take up these compounds, and many normal controls have high uptake. Sorting out the
importance of these findings will require extended follow up of affected individuals. In
addition, there is significant evidence that the insoluble fibrillar amyloid in plaques that
amyloid agents bind might not be the most relevant form of amyloid. In fact the earliest
cognitive changes correlate with soluble diffusible amyloid species [40-42], By focusing
on changes in lysosomal biochemistry, it is possible that our agent might identify
metabolically abnormal cells and tissues before there is substantial amyloid accumulation
or deposition.

2.5

Conclusions
Here we present our first animal data in development of an MRI contrast agent to

quantify enzymatic activity in an intact animal and its application to AD.

Despite our

selection of an AD mouse model that does not have a large change in Cat-D expression
from controls at 1 year of age, our data demonstrates a clear difference in the uptake and
retention pattern of Tm3+-DOTA-CAT over time. Therefore, this agent shows significant
potential as a molecular imaging probe for AD.

Future studies will extend our

understanding of the uptake and retention characteristics of this agent across different AD
mouse strains and across the lifespan of the animals, with the goal being to identify the
earliest time point in which we can distinguish control from AD. Future studies will also
examine the potential for this agent to identify specific cancers with known elevation of
Cat-D.
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Chapter 3: Contributions and Future Work
3.1

Contributions
The major contribution of this thesis was the characterization of the cellular and

in-vivo uptake and retention of a novel MRI contrast agent targeted to cathepsin-D. In the
work described within our first publication, we demonstrated several key features: 1) the
MRI tag was successfully detected using OPARACHEE contrast, 2) the fluorescent probe
was observed under confocal microscopy, 3) cathepsin-D was able to recognize and
correctly cleave the contrast agent, and 4) the cell-penetrating peptide portion of the
compound enabled increased cellular uptake into neurons.
The work presented in Chapter 2 which forms the main body of this thesis builds
upon our previous contrast agent characterization and provides further verification of
uptake and retention in an in-vivo animal model. More specifically: 1) Ti relaxivity was
measured using version of the agent that contained gadolinium, 2) fluorescence sensitivity
was measured (in nanomolar concentrations), 3) cellular uptake and rentention into
neurons was quantified, 4) cathepsin-D protein expression was assessed in a transgenic
model of AD, 5) and the cortical and hippocampal uptake and retention of the contrast
agent was examined within the brain in transgenic AD mice and control mice. The
cathepsin-D targeted agent studied continues to show promise as a novel means of
visualizing early pathological changes associated with Alzheimer’s disease.
This final chapter will describe the limitations, preliminary results, and future
directions for continued development of these targeted MRI contrast agents.
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3.2

Mouse Models with Increased Cathepsin-D Expression
An enhanced understanding of the increased expression of the lysosomal protein

Cat-D will be important in determining future studies of contrast agent uptake and
retention. For instance, in our previous study we compared Cat-D expression in one year
old transgenic mice to control mice. However, greater differences in Cat-D expression
may have been present between these groups at earlier time points (Figure 3.1).
Therefore, it would be beneficial to determine the time point that maximizes differences
in Cat-D expression between the transgenic and control mice. For example, if one were
to check the Cat-D levels for these mice at three or six months, there may be a larger
variation in Cat-D expression between the two groups. A larger difference in Cat-D
expression between the models would allow for a better understanding of the specific
uptake and retention of contrast agent. An expanded search for an optimal mouse model
would evaluate several different strains of transgenic Alzheimer’s mice and compare their
Cat-D expression at various time points.

The goal of these studies would be to

characterize the increased and/or rate of change of Cat-D expression of transgenic AD
mice. As a result, model specific age-groups could be chosen to compare contrast agent
uptake and retention.
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Figure 3.1: Hypothetical representation of Cat-D expression of transgenic and control
mice at various ages. Notice that if the Cat-D expression difference is large, for example
indicated by the dotted blue line at 6 months, this time represents the optimal point of
evaluation of contrast agent uptake in-vivo. It is possible that after one year or prior to
three months of age, that both transgenic and control mice display the same level of CatD expression as our western blots have shown.

3.3

In-Vivo MRI Contrast Agent Uptake
At the current time, the Tnr-DOTA-CAT version of contrast agent has not been

detected within in-vivo brain tissues by PARACEST MRI. This limitation is due to the
low sensitivity of PARACEST detection due to the competing effects from endogenous
macromolecules. Two solutions can be proposed to increase the detectability of the
contrast agent in-vivo.

First, a larger concentration of Tm -DOTA-CAT could be

administered in order to achieve greater detection sensitivity of the agent in-vivo.
However, care must be taken when the concentration used is greater than the
recommended dose for in-vivo animal studies. Secondly, in-vivo imaging studies could
be performed using the gadolinium metalated version of the contrast agent (lanthanide
metal switch from thulium to gadolinium). The MRI sensitivity of Gd3t-DOTA-CAT
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was shown in chapter two to be greater than clinically used Gd3+-DTPA (Magnevist®) at
9.4 Tesla. In a preliminary study, a single Alzheimer’s Precursor Protein (APP) mouse
obtained as a gift from Richard Rozmahel was injected with 2 mM Gd3+-DOTA-CAT
during imaging on a 9.4T MRI scanner [1], These transgenic APP mice exhibit many of
the histopathological changes of AD in humans [2], Figure 3.2 illustrates a coronal slice
of the mouse brain with highlighted regions of interest post-injection.

Non-cerebral

vasculature, cerebral vasculature, and whole brain regions were highlighted in white,
purple, and red respectively. Seven minutes of baseline scanning was performed prior to
injection of Gd3+-DOTA-CAT.

Figure 3.2: In-vivo MRI detection of Gd3+-DOTA-CAT using a Ti-weighted spin-echo
pulse sequence. Three regions of interest were examined: whole brain (Region 1; outlined
in red), non-cerebral vasculature (Region 2; outlined in purple), and cerebral vasculature
(Region 3; outlined in white).

Signal intensity was measured over time pre-, during, and post-injection in these
regions of interest (Figure 3.3). The non-cerebral blood vessel signal (Region 2) intensity
increased by a maximum of 45%, the cerebral blood vessel signal (Region 3) increased by
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14% and the whole brain signal (Region 1) changed by approximately 3% post-injection.
Injection of agent occurred at the seven minute mark. Examining the whole brain signal,
it is difficult to discern the difference in signal from small blood vessels compared to
contrast agent that has been taken up into the brain tissues. Histological sections would
confirm the presence of contrast agent within the brain tissues in future follow up studies.
This mouse had a decline in its vital signs at 16 minutes post-injection.
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Figure 3.3: Quantitative uptake of Gd3+-DOTA-CAT in the APP mouse brain. Signal
intensity as a function of time following normalization to 100 at baseline.
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3.4 Toxicology and Safety of Contrast Agents
Pharmacokinetics of each new agent tested in-vivo must be evaluated to determine
their metabolism and clearance from the body. Along with the previous injection study
from Chapter 2, the liver and kidneys were extracted to examine contrast agent uptake at
various time points post-injection (30, 60, 120 minutes). These tissues will be examined
ex-vivo or post-mortem for uptake of contrast agent either using MRI or through
histology. This information would be highly valuable in determining the half-life of the
agent within the body and would be critical to move this contrast agent from a pre-clinical
to a clinical phase. Further characterization of the safety parameters would also be of
significant importance.

3.5 Limitations to Contrast Agent Design
Both the thulium and gadolinium versions of contrast agent described in this thesis
are of a preliminary configuration that may be modified in future studies to maximize
their in-vivo potential.
One such molecular modification to both contrast agents would be PEGylation to
increase the lifetime of the contrast agents within the blood [3], In addition to longer
post-injection

lifespan,

immunologically inert [4],

PEGylation

reduces

metabolic

degradation,

and

is

PEGylation is the process of adding polyethelene glycol

polymer chains to a molecule. This modification is typically performed on compounds
such as contrast agents or drugs. PEGylation has been approved by the Food and Drug
Administration (FDA) and is currently used in a number of drugs on the market today [5],
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A second modification to the contrast agent could involve adding the capability
for fluorescence resonance energy transfer (FRET) to more directly measure enzymatic
activity in-vivo. FRET imaging would allow the contrast agent to fluorescence only when
it is less than 10 nm from the protein of interest [6, 7]. This alteration would ultimately
enable true recognition of the interaction between Cat-D and contrast agent at the
molecular level. Lastly, cell viability studies could be extended to include assays for a
more sensitive measure of cellular death. However, a recent paper on the toxicity of a
OI

similar contrast agent Eu -DOTA-(Gly)4 demonstrated that DOTA-caged MR contrast
agents were even less toxic than their gadolinium counterparts [8],

3.6 Limitations to Uptake Studies
In order to provide proper controls for each new contrast agent, several modified
forms of the agent must be created to examine their uptake and retention. Two of the four
major components of the contrast agent that could be altered are the cell-penetrating
peptide (CPP) and the Cat-D recognition sequences. By evaluating these regions, the true
specificity and retention of contrast agents would be determined with the appropriate
controls. For instance, the cell-penetrating peptide or TAT region of the compound
should be removed to evaluate the enhanced uptake of compound in comparison to the
original agent. The CPP may be cleaved or removed in its entirety to model its efficacy
(Figure 3.4). These studies may be performed both in-vitro and in-vivo to evaluate uptake
of contrast agent. The second region to be modified would be the Cat-D recognition site.
The amino acid sequence should be scrambled so that the Cat-D enzyme would be unable
to cleave at this site. The effect of this change would be to evaluate how well Cat-D
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recognizes and cleaves the compound but also to evaluate the amount of time the agent is
retained within biological tissues.
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Figure 3.4: Design of control contrast agents to evaluate uptake efficiency of the targeted
Cat-D contrast agent. By modifying the CPP portion of the compound, the difference in
uptake within biological samples may be evaluated. Scrambling the Cat-D recognition
sequence may provide additional information on the targeting and retention of contrast
agent within biological tissues.

3.7 Future of Contrast Agents in Imaging Alzheimer’s Disease
Novel biomarkers will continue to be developed in order to diagnose, monitor or
predict pre-symptomatic AD. The most important feature of novel biomarkers will be
their ability to specifically identify a particular disease mechanism. As our understanding
of Alzheimer’s disease pathology increases, the type of biomarkers being developed for
certain targets may change.

In addition, one biomarker may not necessarily provide

enough evidence to diagnose an individual but rather several biomarkers may be required
indicating a progression of AD.
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